sertaconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 2434 99592-32-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sertaconazole
  • FI 7045
  • sertaconazole nitrate
  • FI-7045
  • Molecular weight: 437.76
  • Formula: C20H15Cl3N2OS
  • CLOGP: 6.16
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 27.05
  • ALOGS: -4.84
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.927 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.845 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.825 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 43.351 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 0.150 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 0.200 % Moderate 0.72
herg hERG pIC50 5.412 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 59.566 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 128.825 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 0.450 % Moderate 0.72
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 41
kinase-selectivity-class AKT3,AXL,BRAF,EIF2AK3,GRK2,PDK4,PIK3CB,PIK3CD,SIK2 9
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.721 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 76.208 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 0.160 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.245 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.650 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 70.958 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.570 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 0.190 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 1.081 uM Moderate 0.72

Approvals:

DateAgencyCompanyOrphan
Dec. 10, 2003 FDA VALEANT LUXEMBOURG

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urethral valves 96.28 55.05 11 99 250 42620975

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AC14 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF19 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:59683 antipruritic drug
CHEBI has role CHEBI:77884 EC 1.14.13.70 (sterol 14α-demethylase) inhibitor

Related Drugs by ATC class:

D01AC Imidazole and triazole derivatives 20 drugs
bifonazolechlormidazoleclotrimazoleeberconazoleeconazoleefinaconazolefenticonazolefluconazoleflutrimazoleisoconazoleketoconazolelanoconazole show all 20 →
G01AF Imidazole derivatives 16 drugs
azanidazolebutoconazoleclotrimazoleeconazolefenticonazoleflutrimazoleisoconazoleketoconazolemetronidazolemiconazoleomoconazoleornidazole show all 16 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholinesterase Enzyme IC50 7 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 5.08 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR WOMBAT-PK CHEMBL
Cholinesterase Enzyme IC50 5.13 CHEMBL

External reference:

IDSource
4021471 VUID
N0000148855 NUI
D06883 KEGG_DRUG
99592-39-9 SECONDARY_CAS_RN
4021471 VANDF
C0074391 UMLSCUI
CHEBI:82866 CHEBI
CHEMBL1201196 ChEMBL_ID
CHEMBL1200725 ChEMBL_ID
DB01153 DRUGBANK_ID
C061131 MESH_SUPPLEMENTAL_RECORD_UI
6008 INN_ID
72W71I16EG UNII
65863 PUBCHEM_CID
236601 RXNORM
17708 MMSL
006417 NDDF
006418 NDDF
409280001 SNOMEDCT_US
409281002 SNOMEDCT_US
426726001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ERTACZO HUMAN PRESCRIPTION DRUG LABEL 1 21695-454 CREAM 20 mg TOPICAL ANDA 21 sections
Ertaczo HUMAN PRESCRIPTION DRUG LABEL 1 73159-004 CREAM 20 mg TOPICAL NDA 23 sections
Ertaczo HUMAN PRESCRIPTION DRUG LABEL 1 85437-004 CREAM 20 mg TOPICAL NDA 23 sections